🇺🇸 FDA
Patent

US 10765666

Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering

granted A61KA61K31/437A61P

Quick answer

US patent 10765666 (Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering) held by OVID THERAPEUTICS INC. expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OVID THERAPEUTICS INC.
Grant date
Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/437, A61P, A61P25/14